Shares of Humacyte sank 10.2% to $0.64 ahead of the company's Q2 2026 earnings release, scheduled for 8:00 a.m. Eastern today. The sell-off, against a modestly higher broad market, signals that investors are bracing for disappointing numbers from a biotech that has been burning cash faster than it can sell its one approved product — a lab-grown blood vessel used in vascular trauma surgery.
• The Only Approved Product Isn't Selling Fast Enough
In Q1, Humacyte sold just 29 units of its bioengineered vessel for $0.5 million in revenue, up from 5 units a year earlier . Wall Street expects roughly $1.12 million in Q2 revenue and a $0.10-per-share loss. Last quarter the company reported a -$0.116 EPS against expectations of -$0.09 — a wide miss that spooked holders. Even if Q2 revenue doubles from Q1, these are tiny figures for a company that has spent years and hundreds of millions reaching the market.
• The Cash Situation Is Getting Dire
As of March 31, Humacyte had $48.5 million in cash, but its own SEC filing warned it "will not have sufficient liquidity to fund its operations beyond one year" without new sales or capital — language that raises "substantial doubt about the Company's ability to continue as a going concern."
To bridge the gap, Humacyte raised $50 million in a June stock offering at $1.05 per share — a price now 39% above where it trades. A 25% workforce reduction (45 employees) aims to save roughly $14.3 million through year-end , but cost cuts alone can't replace revenue growth.
• Nasdaq Has Already Flagged the Stock — Twice
On July 31, Nasdaq notified Humacyte again that its stock had closed below the $1.00 minimum bid price for 30 consecutive days; the company has until January 27, 2027, to regain compliance . This is the second warning this year — the first came in May, and the stock briefly recovered above $1 before sliding back . If Humacyte can't hold $1.00, a delisting or reverse stock split becomes a real possibility, either of which would further erode investor confidence.
• The Pipeline Offers Hope, but Costs Money
Positive Phase 3 trial results for a dialysis-access version of its blood vessel prompted plans for a new FDA application in the second half of 2026 . Analysts maintain a favorable view, with four buy ratings and price targets ranging from $1.00 to $4.00 . But every new trial and regulatory filing demands cash this company barely has. Today's earnings call will tell investors whether sales momentum is real — or whether Humacyte's science remains a promise the balance sheet can no longer afford to keep.